Phoenix Biotechnology, Inc. (PBI)'s Focus
Phoenix Biotechnology, Inc., has been exploring the health-related benefits of a novel extract of Nerium oleander for the past 20 years. The company has developed a supercritical CO2 extraction of Nerium oleander into a new botanical drug – PBI-05204.
PBI-05204 is a ‘botanical drug’ that has been through initial FDA review and approved for the Phase I and Phase II clinical trials which were conducted in the United States. These trials have shown that this oral (capsule) formulation is safe for administration to patients without undue toxicity.
A distinction of PBI-05204 is that research has consistently proven that this drug crosses the blood brain barrier which opens up several potential applications. Extensive research has been done in the following areas: Antiviral, Cancer, and Neurodegenerative Diseases.
“The Botanical Drug PBI-05204, a Supercritical CO2 Extract of Nerium Oleander, Is Synergistic With Radiotherapy in Models of Human Glioblastoma". Frontiers in Pharmacology, 23 March 2022.
Glioblastoma multiform (GBM) is the most common type of brain cancer. Despite intense therapeutic efforts, patient survival is low indicating the need for new therapeutic strategies. The research in this article demonstrates that not only does PBI-05204 work well against human glioblastoma using cell culture and animal models of GBM, but the therapeutic result is enhanced with the addition of radiotherapy. Mechanistic reasons for this synergy are presented in the article.
“Antiviral activity of oleandrin and a defined extract of Nerium oleander against SARS-CoV-2". Biomedicine & Pharmacotherapy.
With continued expansion of COVID-19 caused by the severe respiratory syndrome 2 (SARS-CoV-2) antiviral therapies as well as effective vaccines are desperately needed. This article presents evidence for the significant inhibition of SARS-CoV-2 by oleandrin and the company's experimental product PBI-06150.